Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Checkpoint Therapeutics Inc (CKPT)

Checkpoint Therapeutics Inc (CKPT)
4.05 x 104 4.06 x 12
Post-market by (Cboe BZX)
4.04 unch (unch) 04/23/25 [NASDAQ]
4.05 x 104 4.06 x 12
Post-market 4.06 +0.02 (+0.50%) 17:46 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.04
Day High
4.05
Open 4.04
Previous Close 4.04 4.04
Volume 1,410,094 1,410,094
Avg Vol 1,739,185 1,739,185
Stochastic %K 88.38% 88.38%
Weighted Alpha +65.02 +65.02
5-Day Change +0.02 (+0.50%) +0.02 (+0.50%)
52-Week Range 1.38 - 4.50 1.38 - 4.50
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 338,407
  • Shares Outstanding, K 83,764
  • Annual Sales, $ 40 K
  • Annual Income, $ -56,240 K
  • EBIT $ -38 M
  • EBITDA $ -38 M
  • 60-Month Beta 1.21
  • Price/Sales 8,253.82
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 211.23% ( -59.06%)
  • Historical Volatility 8.29%
  • IV Percentile 74%
  • IV Rank 28.40%
  • IV High 640.26% on 04/29/24
  • IV Low 41.08% on 10/03/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 146
  • Volume Avg (30-Day) 98
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 8,076
  • Open Int (30-Day) 16,426

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +302,827.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.94 +2.54%
on 04/09/25
Period Open: 4.07
4.07 -0.74%
on 03/26/25
-0.03 (-0.74%)
since 03/21/25
3-Month
2.37 +70.82%
on 03/07/25
Period Open: 2.95
4.08 -0.98%
on 03/10/25
+1.09 (+36.95%)
since 01/23/25
52-Week
1.38 +192.75%
on 05/01/24
Period Open: 1.43
4.50 -10.22%
on 12/02/24
+2.61 (+181.53%)
since 04/23/24

Most Recent Stories

More News
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

FBIO : 1.5800 (+3.27%)
CKPT : 4.04 (unch)
Durable Goods, Home Sales in U.S. Due Next Week

U.S. Monday Economic Lookahead S&P flash U.S. services PMI (March) S&P flash ...

CNM : 50.43 (+1.49%)
HUMA : 1.4700 (+7.30%)
MKC : 76.60 (+1.14%)
BRZE : 28.34 (+1.47%)
DLTR : 83.43 (+1.55%)
TMC : 2.55 (+8.05%)
EPAC : 39.07 (+1.74%)
DIV.TO : 2.85 (+0.71%)
KBH : 53.47 (-0.35%)
LULU : 265.85 (+1.58%)
CKPT : 4.04 (unch)
KEI.TO : 9.56 (-2.05%)
Adoption of Autonomous Drones Rises for Military Operations Fueled by Cutting-Edge Technology

EQNX::TICKER_START (NASDAQ:ZENA),(NYSE:UAVS),(NASDAQ:RCAT),(NASDAQ:ONDS),(NASDAQ:DPRO),(CSE:DPRO),(NASDAQ:CKPT) EQNX::TICKER_END

RCAT : 5.00 (+4.60%)
DPRO.CN : 3.6400 (+1.68%)
CKPT : 4.04 (unch)
ZENA : 2.19 (-0.45%)
DPRO : 2.52 (-1.18%)
ONDS : 0.8419 (+2.66%)
UAVS : 1.0600 (+3.92%)
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END

ONCY : 0.5666 (-5.57%)
CKPT : 4.04 (unch)
PSNL : 3.68 (+7.92%)
ONC.TO : 0.79 (-5.95%)
TEM : 49.55 (+14.62%)
CRDF : 2.94 (-3.61%)
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

/CNW/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major...

ONCY : 0.5666 (-5.57%)
CKPT : 4.04 (unch)
PSNL : 3.68 (+7.92%)
ONC.TO : 0.79 (-5.95%)
TEM : 49.55 (+14.62%)
CRDF : 2.94 (-3.61%)
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

/CNW/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...

ONCY : 0.5666 (-5.57%)
CKPT : 4.04 (unch)
LLY : 829.42 (+0.23%)
ONC.TO : 0.79 (-5.95%)
OSTX : 1.5500 (+1.97%)
CRDF : 2.94 (-3.61%)
FDA Approves Checkpoint Therapeutics' UNLOXCYT™ for Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics announces FDA approval of UNLOXCYT™ for treating advanced cutaneous squamous cell carcinoma in non-surgical patients.Quiver AI SummaryCheckpoint Therapeutics, Inc. announced that...

CKPT : 4.04 (unch)
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

FBIO : 1.5800 (+3.27%)
CKPT : 4.04 (unch)
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

/CNW/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among people under...

ONCY : 0.5666 (-5.57%)
CKPT : 4.04 (unch)
RCUS : 8.11 (+0.25%)
BCTX : 5.43 (+1.50%)
ONC.TO : 0.79 (-5.95%)
AKYA : 1.2700 (+8.55%)
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is...

ONCY : 0.5666 (-5.57%)
CKPT : 4.04 (unch)
RCUS : 8.11 (+0.25%)
BCTX : 5.43 (+1.50%)
AKYA : 1.2700 (+8.55%)
ONC.TO : 0.79 (-5.95%)

Business Summary

Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New...

See More

Key Turning Points

3rd Resistance Point 4.06
2nd Resistance Point 4.05
1st Resistance Point 4.05
Last Price 4.04
1st Support Level 4.04
2nd Support Level 4.03
3rd Support Level 4.03

See More

52-Week High 4.50
Last Price 4.04
Fibonacci 61.8% 3.31
Fibonacci 50% 2.94
Fibonacci 38.2% 2.57
52-Week Low 1.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective